ZA200303669B - Combination therapy for estrogen-dependent disorders. - Google Patents

Combination therapy for estrogen-dependent disorders. Download PDF

Info

Publication number: ZA200303669B
Authority: ZA; South Africa
Prior art keywords: use according; cancer; aromatase inhibitor; lhrh agonist; triptorelin
Prior art date: 2000-11-16

Application number

ZA200303669A

Other languages

English (en)

Inventor

Dinesh Purandare

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-16

Filing date

2003-05-13

Publication date

2004-05-13

2003-05-13 Application filed by Upjohn Co filed Critical Upjohn Co

2004-05-13 Publication of ZA200303669B publication Critical patent/ZA200303669B/en

Links

230000001419 dependent effect Effects 0.000 title claims description 24
229940011871 estrogen Drugs 0.000 title claims description 7
239000000262 estrogen Substances 0.000 title claims description 7
238000002648 combination therapy Methods 0.000 title description 5
239000000556 agonist Substances 0.000 claims description 47
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 45
102100024028 Progonadoliberin-1 Human genes 0.000 claims description 45
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 45
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 45
239000003886 aromatase inhibitor Substances 0.000 claims description 41
229940122815 Aromatase inhibitor Drugs 0.000 claims description 39
206010028980 Neoplasm Diseases 0.000 claims description 38
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 31
206010006187 Breast cancer Diseases 0.000 claims description 27
208000026310 Breast neoplasm Diseases 0.000 claims description 26
229960004824 triptorelin Drugs 0.000 claims description 23
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 22
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 21
201000011510 cancer Diseases 0.000 claims description 21
229960000255 exemestane Drugs 0.000 claims description 21
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 19
238000011282 treatment Methods 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 18
239000003163 gonadal steroid hormone Substances 0.000 claims description 18
108010069236 Goserelin Proteins 0.000 claims description 17
229960004421 formestane Drugs 0.000 claims description 17
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical group C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 16
229960002913 goserelin Drugs 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 14
239000005557 antagonist Substances 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 11
206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 10
206010033128 Ovarian cancer Diseases 0.000 claims description 10
229950011548 fadrozole Drugs 0.000 claims description 10
238000009472 formulation Methods 0.000 claims description 10
229940088597 hormone Drugs 0.000 claims description 10
239000005556 hormone Substances 0.000 claims description 10
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 10
229960004338 leuprorelin Drugs 0.000 claims description 10
ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical group C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 claims description 9
108010000817 Leuprolide Proteins 0.000 claims description 9
230000000694 effects Effects 0.000 claims description 9
229960001771 vorozole Drugs 0.000 claims description 9
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
229960000294 triptorelin pamoate Drugs 0.000 claims description 8
210000001672 ovary Anatomy 0.000 claims description 7
230000005764 inhibitory process Effects 0.000 claims description 6
108010023617 abarelix Proteins 0.000 claims description 5
AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 5
229960002184 abarelix Drugs 0.000 claims description 5
229960002932 anastrozole Drugs 0.000 claims description 5
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 5
229960003881 letrozole Drugs 0.000 claims description 5
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
108010037003 Buserelin Proteins 0.000 claims description 4
229960002719 buserelin Drugs 0.000 claims description 4
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
230000002611 ovarian Effects 0.000 claims description 4
102000014654 Aromatase Human genes 0.000 claims description 3
108010078554 Aromatase Proteins 0.000 claims description 3
229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 3
NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 2
WDYSQADGBBEGRQ-APSDYLPASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2r,3r,4r,5r,6s) Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WDYSQADGBBEGRQ-APSDYLPASA-N 0.000 claims description 2
HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 2
PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 claims description 2
108700013943 AN 207 Proteins 0.000 claims description 2
201000009030 Carcinoma Diseases 0.000 claims description 2
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 2
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
108700029108 MI 1544 Proteins 0.000 claims description 2
108010021717 Nafarelin Proteins 0.000 claims description 2
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
206010057644 Testis cancer Diseases 0.000 claims description 2
208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
108010070670 antarelix Proteins 0.000 claims description 2
229950010887 avorelin Drugs 0.000 claims description 2
108700008462 cetrorelix Proteins 0.000 claims description 2
229960003230 cetrorelix Drugs 0.000 claims description 2
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
108700025485 deslorelin Proteins 0.000 claims description 2
229960005408 deslorelin Drugs 0.000 claims description 2
208000037828 epithelial carcinoma Diseases 0.000 claims description 2
108700032141 ganirelix Proteins 0.000 claims description 2
GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 2
229960003794 ganirelix Drugs 0.000 claims description 2
210000004602 germ cell Anatomy 0.000 claims description 2
239000002474 gonadorelin antagonist Substances 0.000 claims description 2
239000000017 hydrogel Substances 0.000 claims description 2
230000002163 immunogen Effects 0.000 claims description 2
239000007943 implant Substances 0.000 claims description 2
201000005202 lung cancer Diseases 0.000 claims description 2
208000020816 lung neoplasm Diseases 0.000 claims description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
229960002333 nafarelin Drugs 0.000 claims description 2
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 2
210000003101 oviduct Anatomy 0.000 claims description 2
201000002528 pancreatic cancer Diseases 0.000 claims description 2
208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
108010092834 ramorelix Proteins 0.000 claims description 2
229950000277 ramorelix Drugs 0.000 claims description 2
201000003120 testicular cancer Diseases 0.000 claims description 2
229950011372 teverelix Drugs 0.000 claims description 2
206010046766 uterine cancer Diseases 0.000 claims description 2
229940126062 Compound A Drugs 0.000 claims 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
230000002779 inactivation Effects 0.000 claims 1
-1 methyltyrosyl-N6-(nicotinoyl)-D-lysyl-leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide Chemical compound 0.000 claims 1
238000000034 method Methods 0.000 description 10
239000008194 pharmaceutical composition Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000002280 anti-androgenic effect Effects 0.000 description 4
239000000051 antiandrogen Substances 0.000 description 4
208000035269 cancer or benign tumor Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
241000282412 Homo Species 0.000 description 3
229940046836 anti-estrogen Drugs 0.000 description 3
230000001833 anti-estrogenic effect Effects 0.000 description 3
239000000328 estrogen antagonist Substances 0.000 description 3
201000007741 female breast cancer Diseases 0.000 description 3
201000002276 female breast carcinoma Diseases 0.000 description 3
238000009806 oophorectomy Methods 0.000 description 3
241001132374 Asta Species 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
229940046844 aromatase inhibitors Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
201000005825 prostate adenocarcinoma Diseases 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
206010057654 Breast cancer female Diseases 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
239000003098 androgen Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
229940006408 exemestane 25 mg Drugs 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
230000024717 negative regulation of secretion Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200303669A 2000-11-16 2003-05-13 Combination therapy for estrogen-dependent disorders. ZA200303669B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71460500A	2000-11-16	2000-11-16

Publications (1)

Publication Number	Publication Date
ZA200303669B true ZA200303669B (en)	2004-05-13

Family

ID=24870727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200303669A ZA200303669B (en)	2000-11-16	2003-05-13	Combination therapy for estrogen-dependent disorders.

Country Status (16)

Country	Link
EP (1)	EP1341549A2 (cs)
JP (1)	JP2004536022A (cs)
KR (1)	KR20030051828A (cs)
CN (1)	CN1498112A (cs)
AU (1)	AU2002230464A1 (cs)
BR (1)	BR0115423A (cs)
CA (1)	CA2428249A1 (cs)
CZ (1)	CZ20031349A3 (cs)
EA (1)	EA200300572A1 (cs)
IL (1)	IL155817A0 (cs)
MX (1)	MXPA03004195A (cs)
NO (1)	NO20032206L (cs)
NZ (1)	NZ525720A (cs)
PL (1)	PL365904A1 (cs)
WO (1)	WO2002039995A2 (cs)
ZA (1)	ZA200303669B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1286704T3 (da)	2000-06-02	2014-09-22	Univ Texas	Ethylendicystein (EC)-glucose analoge konjugater
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) *	2005-04-02	2005-05-11	Medical Res Council	Combination treatment methods
EP1891964A1 (en) *	2006-08-08	2008-02-27	AEterna Zentaris GmbH	Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008128786A1 (en) *	2007-04-23	2008-10-30	Bayer Schering Pharma Aktiengesellschaft	Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
CN101775054B (zh) *	2010-02-05	2012-12-26	常州佳尔科药业集团有限公司	4-羟基-4-烯-3-酮甾族化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9911582D0 (en) *	1999-05-18	1999-07-21	Pharmacia & Upjohn Spa	Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9930839D0 (en) *	1999-12-30	2000-02-16	Pharmacia & Upjohn Spa	Process for treating gynecomastia

2001
- 2001-11-06 KR KR10-2003-7006608A patent/KR20030051828A/ko not_active Withdrawn
- 2001-11-06 CZ CZ20031349A patent/CZ20031349A3/cs unknown
- 2001-11-06 WO PCT/US2001/043847 patent/WO2002039995A2/en not_active Ceased
- 2001-11-06 EA EA200300572A patent/EA200300572A1/ru unknown
- 2001-11-06 CA CA002428249A patent/CA2428249A1/en not_active Abandoned
- 2001-11-06 AU AU2002230464A patent/AU2002230464A1/en not_active Abandoned
- 2001-11-06 NZ NZ525720A patent/NZ525720A/en unknown
- 2001-11-06 PL PL01365904A patent/PL365904A1/xx not_active Application Discontinuation
- 2001-11-06 IL IL15581701A patent/IL155817A0/xx unknown
- 2001-11-06 BR BR0115423-0A patent/BR0115423A/pt not_active IP Right Cessation
- 2001-11-06 EP EP01990699A patent/EP1341549A2/en not_active Withdrawn
- 2001-11-06 CN CNA018189385A patent/CN1498112A/zh active Pending
- 2001-11-06 MX MXPA03004195A patent/MXPA03004195A/es unknown
- 2001-11-06 JP JP2002542370A patent/JP2004536022A/ja active Pending
2003
- 2003-05-13 ZA ZA200303669A patent/ZA200303669B/en unknown
- 2003-05-15 NO NO20032206A patent/NO20032206L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2428249A1 (en)	2002-05-23
IL155817A0 (en)	2003-12-23
NZ525720A (en)	2006-12-22
EA200300572A1 (ru)	2004-06-24
EP1341549A2 (en)	2003-09-10
WO2002039995A2 (en)	2002-05-23
BR0115423A (pt)	2005-12-13
WO2002039995A3 (en)	2003-05-01
MXPA03004195A (es)	2003-09-22
KR20030051828A (ko)	2003-06-25
CZ20031349A3 (cs)	2004-05-12
NO20032206D0 (no)	2003-05-15
NO20032206L (no)	2003-07-15
AU2002230464A1 (en)	2002-05-27
WO2002039995A9 (en)	2003-02-06
JP2004536022A (ja)	2004-12-02
CN1498112A (zh)	2004-05-19
PL365904A1 (en)	2005-01-10

Publication	Publication Date	Title
Felberbaum et al.	1998	Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
EP0195015B1 (en)	1992-05-13	Pharmaceutical composition for combination therapy of hormone dependent cancers
Resta et al.	2023	Gonadotropin-releasing hormone (GnRH)/GnRH receptors and their role in the treatment of endometriosis
MXPA04009455A (es)	2005-01-25	Aumento de produccion endogena de gonadotropina.
Felberbaum et al.	2000	Clinical application of GnRH-antagonists
Chrisp et al.	1991	Goserelin: a review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions
IE902459A1 (en)	1991-02-13	Combination therapy for the prophylaxis and/or treatment of¹benign prostatic hyperplasia
Gleave et al.	1999	Prostate cancer: 9. Treatment of advanced disease
KR19990082080A (ko)	1999-11-15	부인과 질환을 치료하기 위한 lhrh 유사 물질 및 항에스트로겐을 포함하는 제약적 배합 제제
Klijn et al.	1984	Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer
AU2002230464A1 (en)	2002-05-27	Combination therapy for estrogen-dependent disorders
Goldspiel et al.	1991	Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer
Klijn	1992	LH-RH agonists in the treatment of metastatic breast cancer: ten years’ experience
RU2181598C2 (ru)	2002-04-27	Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения
US5023234A (en)	1991-06-11	Combination male breast cancer therapy
US20120004182A1 (en)	2012-01-05	Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
WO2002039996A2 (en)	2002-05-23	Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
US20040043938A1 (en)	2004-03-04	Combination therapy for estrogen-dependent disorders
Kotlyar et al.	2021	Eliminating hormones with orally active gonadotropin-releasing hormone antagonists
Fluker	2000	Gonadotropin-releasing hormone antagonists
EP1029868A1 (en)	2000-08-23	Hysteromyoma remedy containing dienogest as the active ingredient
HK1066169A (en)	2005-03-18	Combination therapy for estrogen-dependent disorders
Forti	1988	Clinicai applications of GnRH analogs
Adegoke et al.	2020	GnRH Antagonists in the Treatment of Uterine Fibroids
HU199694B (en)	1990-03-28	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives